Exane Derivatives Madrigal Pharmaceuticals, Inc. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Exane Derivatives holds 1,707 shares of MDGL stock, worth $532,584. This represents 0.08% of its overall portfolio holdings.
Number of Shares
1,707
Previous 1,707
-0.0%
Holding current value
$532,584
Previous $167,000
26.95%
% of portfolio
0.08%
Previous 0.05%
Shares
3 transactions
Others Institutions Holding MDGL
# of Institutions
297Shares Held
22MCall Options Held
819KPut Options Held
640K-
Janus Henderson Group PLC London, X02.48MShares$773 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$637 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$633 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$622 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$616 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.34B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...